CymaBay Therapeutics Inc. (CBAY)
NASDAQ: CBAY
· Real-Time Price · USD
32.48
0.01 (0.03%)
At close: Mar 21, 2024, 9:00 PM
CymaBay Therapeutics Balance Sheet Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Cash & Equivalents | 206.53M | 273.72M | 35.48M | 59.15M | 20.29M | 30.69M | 52.75M | 74M | 125.81M | 68.96M | 32.9M | 43.33M |
Short-Term Investments | 187.72M | 165.06M | 178.36M | 177.22M | 115.19M | 122.72M | 111.13M | 114.56M | 60.73M | 44.83M | 73.24M | 82.13M |
Long-Term Investments | 22.36M | n/a | n/a | n/a | n/a | n/a | 6.87M | 4.88M | 8.07M | n/a | n/a | n/a |
Other Long-Term Assets | 2.8M | 2.88M | 1.85M | 1.73M | 2.91M | 3.08M | 3.03M | 2.45M | 1.72M | 1.72M | 1.45M | 1.45M |
Receivables | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 69K | 227K | 265K |
Inventory | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Current Assets | 9.55M | 8.88M | 10.23M | 6.36M | 2.59M | 1.71M | 2.73M | 3.49M | 4.56M | 5.72M | 7.45M | 7.55M |
Total Current Assets | 403.8M | 447.66M | 224.07M | 242.72M | 138.07M | 155.12M | 166.61M | 192.05M | 191.1M | 119.58M | 113.81M | 133.27M |
Property-Plant & Equipment | 5.72M | 510K | 725K | 866K | 870K | 1.04M | 1.21M | 1.26M | 1.43M | 1.6M | 1.78M | 1.96M |
Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 30.88M | 3.39M | 2.58M | 2.6M | 3.78M | 4.12M | 11.11M | 8.6M | 11.22M | 3.33M | 3.23M | 3.41M |
Total Assets | 434.69M | 451.05M | 226.65M | 245.32M | 141.85M | 159.25M | 177.72M | 200.64M | 202.32M | 122.9M | 117.04M | 136.68M |
Account Payables | 3.83M | 2.73M | 4.59M | 1.63M | 1.1M | 479K | 866K | 199K | 2.73M | 764K | 1.05M | 1.61M |
Deferred Revenue | 1.69M | 1.63M | 1.63M | 33.73M | n/a | n/a | n/a | n/a | -567K | n/a | n/a | n/a |
Short-Term Debt | 10.01M | 206K | 374K | 537K | 664K | 639K | 614K | 590K | 567K | 545K | 523K | 502K |
Other Current Liabilities | 21.32M | 15.1M | 11.3M | 10.6M | 13.68M | 11.59M | 11.08M | 13.25M | 15.07M | 10.43M | 7.39M | 5.8M |
Total Current Liabilities | 36.84M | 19.67M | 17.89M | 46.5M | 15.44M | 12.71M | 12.56M | 14.04M | 18.37M | 11.74M | 8.96M | 7.91M |
Long-Term Debt | 104.49M | 104.09M | 99.25M | 94.63M | 90.26M | 86.36M | 82.71M | 79.22M | 51.02M | 24.1M | 988K | 1.13M |
Other Long-Term Liabilities | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Liabilities | 105.59M | 105.19M | 100.35M | 94.63M | 90.26M | 86.36M | 82.71M | 79.22M | 51.02M | 24.1M | 988K | 1.13M |
Total Liabilities | 142.43M | 124.86M | 118.24M | 141.13M | 105.7M | 99.07M | 95.27M | 93.26M | 69.38M | 35.84M | 9.95M | 9.04M |
Total Debt | 114.49M | 104.3M | 99.62M | 95.17M | 90.92M | 87M | 83.32M | 79.81M | 51.58M | 24.65M | 1.51M | 1.63M |
Common Stock | 11K | 18K | 17K | 17K | 8K | 8K | 8K | 8K | 8K | 7K | 7K | 7K |
Retained Earnings | -978.23M | -936.33M | -902.44M | -901.63M | -872.86M | -846.22M | -821.72M | -794.63M | -766.86M | -740.31M | -717.63M | -694.41M |
Comprehensive Income | 144K | -62K | -124K | -70K | -326K | -574K | -441K | -219K | -13K | -1K | 1K | -6K |
Shareholders Equity | 292.26M | 326.19M | 108.41M | 104.19M | 36.15M | 60.18M | 82.46M | 107.38M | 132.94M | 87.06M | 107.09M | 127.65M |
Total Investments | 210.08M | 165.06M | 178.36M | 177.22M | 115.19M | 122.72M | 118M | 119.45M | 60.73M | 44.83M | 73.24M | 82.13M |